La Jolla Pharmaceuticals $LJPC has landed $125 million to back its rollout of Giapreza, a new drug for dangerously low blood pressure that was green-lighted by the FDA late last year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,